Clinical trial · Observational
Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)
Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Approximately 20% of patients diagnosed with Hodgkin lymphoma will eventually experience progression or relapse after first-line treatment, which carries a significant risk of disease-related death. Although several pilot studies have demonstrated high rates of sustained response with the combination of brentuximab vedotin (BV) and chemotherapy, consistent real-world data are still lacking. Moreover, there is no universally accepted salvage chemotherapy regimen in this setting, and clinical practices vary across centers. This study aims to describe the efficacy and toxicity of the BV + bendamustine (B2) regimen in patients with relapsed/refractory Hodgkin lymphoma (R/R HL) treated in France over a 10-year period, with or without an attempt at consolidative transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory Hodgkin Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brentuximab-Vedotin associated with Bendamustine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient with relapsed or refractory Hodgkin Lymphoma
- interventionNames
- Drug: Brentuximab-Vedotin associated with Bendamustine
Primary outcomes (1)
- measure
- Progression free survival (PFS) for the whole cohort
- timeFrame
- From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
- description
- Measured from the time of treatment initiation to the date of event : progression or death
Secondary outcomes (1)
- measure
- Overal survival (OS) for the whole cohort
- timeFrame
- From date of inclusion until the date of death from any cause assessed up to 120 months
- description
- Measured from the time of treatment initiation to the date of death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with relapsed or refractory HL, after at least one first line of treatment * Aged 18 years and over * Having received at least one course of the Brenxutimab-Vedotin J1 and Bendamustine J1 + J2 combination Exclusion Criteria: * Minor patients * Pregnant women
References
Publications (0)
Data not yet available